<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627900</url>
  </required_header>
  <id_info>
    <org_study_id>EK-Vorgang: Verschiedenes</org_study_id>
    <nct_id>NCT00627900</nct_id>
  </id_info>
  <brief_title>Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents</brief_title>
  <acronym>GERSHWIN</acronym>
  <official_title>Model Project for the Reduction of Coronary Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Techniker Krankenkasse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the advent of coronary stents, in-stent restenosis has proven to be the major
      limitation of interventional cardiology, occurring in as many as 30% of patients.
      Drug-eluting stents are specifically designed to prevent the problem of in-stent restenosis.
      They consist of a selective anti-proliferative drug, sirolimus, a controlled-release polymer,
      and a closed-cell stent delivery platform. Upon placement, sirolimus elutes into the vessel
      wall and stops the process of neointimal hyperplasia, thereby significantly reducing the
      incidence of in-stent restenosis.

      The study &quot;Prevention of Coronary Restenosis&quot; examines the effectiveness of sirolimus-eluting
      stents (SES) compared to bare-metal stents (BMS) in patients with coronary stenosis. The goal
      of the study is to examine whether the guideline-supported implantation of SES, despite the
      higher initial cost, improves the quality and economic outcomes of the treatment of patients
      with coronary stenosis. Secondarily, the study evaluates patient quality of life, impairment
      of daily activities, re-intervention rate, as well as an account of the utilisation and
      benefits of the implemented standardised guidelines.

      In this prospective, multi-centre, country-wide cohort study, 658 patients undergoing an
      implantation of a SES for treatment of coronary stenosis were recruited from 35 hospital
      centres. Their treatment and outcomes will be evaluated over a 3-year period by means of
      standardised questionnaires. In addition, information obtained from the patients will be
      confirmed and augmented by telephone interviews with the attending physicians involved in
      their follow-up care.

      In order to appraise the effect of the new therapy, a comparison cohort group of 394 patients
      receiving a BMS was recruited. These patients will be evaluated and observed by the same
      method as those patients receiving a drug-eluting stent, also over 3 years
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <primary_completion_date type="Anticipated">September 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
  </study_design_info>
  <primary_outcome>
    <measure>Cost equivalence of sirolimus-eluting coronary stents versus bare metal stents</measure>
    <time_frame>3,6,12,18,24, 36 months following stent implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE (re-PCI, myocardial infarction, CABG, death)</measure>
    <time_frame>3,6,12,24,36 months after stent implantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">958</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>BMS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Implantation of a bare metal stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SES</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Implantation of a sirolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bare metal stent</intervention_name>
    <description>implantation of a bare metal stent</description>
    <arm_group_label>BMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cypher-Stent (Implantation of a sirolimus-eluting stent)</intervention_name>
    <description>Implantation of a sirolimus-eluting stent</description>
    <arm_group_label>SES</arm_group_label>
    <other_name>Cypher-Stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  indication for implantation of a coronary stent

          -  de novo lesions &lt; or = 30 mm in patients with diabetes

          -  de novo lesions 12-30 mm or RVD 2.5-3.00 mm in patients without diabetes

        Exclusion Criteria:

          -  acute MI

          -  lesion length &gt;30 mm

          -  in-stent restenosis

          -  distal lesion in RVD &lt; 2.25 mm

          -  lesion in left main or bypass vessel

          -  contraindication to Clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan N Willich, MD, MPH, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie</name>
      <address>
        <city>Berlin</city>
        <zip>10098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Brüggenjürgen B, McBride D, Bode C, Hamm CW, Kuck KH, Willich SN. Sirolimus-eluting versus bare-metal stents for the reduction of coronary restenosis: 18-month angiographic results from the GERSHWIN Study. Herz. 2007 Dec;32(8):650-5.</citation>
    <PMID>18060612</PMID>
  </results_reference>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2008</study_first_posted>
  <last_update_submitted>February 24, 2008</last_update_submitted>
  <last_update_submitted_qc>February 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Frau Jena Benkenstein</name_title>
    <organization>Techniker Krankenkasse</organization>
  </responsible_party>
  <keyword>drug-eluting stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

